2-氨基-5-异丙基噻吩-3-甲酸乙酯 | 65416-85-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-氨基-5-异丙基噻吩-3-甲酸乙酯
• 英文名称: ethyl 2-amino-5-isopropylthiophene-3-carboxylate
• 英文别名: 2-Amino-5-(1-methyl-ethyl)-3-thiophencarbonsaeurethylester；ethyl 2-amino-5-(1-methylethyl)-3-thiophenecarboxylate；2-amino-5-isopropylthiophene-3-carboxylic acid ethyl ester；2-amino-5-(1-methylethyl)-3-thiophenecarboxylic acid,ethyl ester；ethyl 2-amino-5-propan-2-ylthiophene-3-carboxylate
• CAS: 65416-85-5
• 化学式: C₁₀H₁₅NO₂S
• mdl: MFCD01922197
• 分子量: 213.301
• InChiKey: CRSNXJLZRGBLAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 安全说明：
  S29/35,S3/7,S36/37
• 危险类别码：
  R20/21/22,R40
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  应存放在室温、避光且处于惰性气体保护的环境中。

反应信息

• 作为反应物：
  描述：

  2-氨基-5-异丙基噻吩-3-甲酸乙酯 在 sodium methylate 、 sodium hydride 作用下， 以 甲醇 为溶剂， 反应 37.0h， 生成 [3-(4-Bromo-2-fluoro-benzyl)-6-isopropyl-2,4-dioxo-3,4-dihydro-2H-thieno[2,3-d]pyrimidin-1-yl]-acetic acid ethyl ester
  参考文献：
  名称：

  Syntheses of substituted 2,4-dioxo-thienopyrimidin-1-acetic acids and their evaluation as aldose reductase inhibitors

  摘要：

  A series of 2,4-dioxo-thieno[2,3-d], [3,2-d] and [3,4-d]pyrimidin-1-acetic acids (2) with a benzyl moiety at the N-3 position were prepared and tested in vitro for aldose reductase inhibitory activity against partially purified enzyme from rat lens. Some of these compounds were also evaluated for inhibition of sorbitol accumulation in the sciatic nerve or lens of streptozotocin-induced diabetic rats in vivo. Among the synthesized compounds, several showed potent aldose reductase inhibitory activity with IC50s in the 10(-8) M range. Particularly, the potencies of non-substituted thieno- (2a and 2aa), 5-methylthieno- (2c), 5,6-dimethylthieno-(2g), 6-isopropylthieno- (2j and 2k), 6-chlorothienopyrimidine (2q) and benzothienopyrimidine (2ac) analogs were approximately equipotent to FK-366 (1A) and Ponalrestat (1B) as references. Although most compounds were inactive in vivo, 2 compounds, 2k and 2q, possessed moderate in vivo activity.

  DOI：

  10.1016/0223-5234(93)90112-r
• 作为产物：
  描述：

  氰乙酸乙酯 、 异戊醛 在 吗啉 、 sulfur 作用下， 以 乙醇 为溶剂， 反应 16.0h， 生成 2-氨基-5-异丙基噻吩-3-甲酸乙酯
  参考文献：
  名称：

  [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS
  [FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES

  摘要：

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。

  公开号：

  WO2021239117A1

文献信息

• Piperazine and homopiperazine compounds
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030153556A1

  公开（公告）日：2003-08-14

  Compounds are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis.

  提供了具有哌嗪或同源哌嗪环的化合物，这些化合物在治疗血栓症方面很有用。
• Piperidinylamino-thieno[2,3-D] pyrimidine compounds
  申请人：Dhanoa S. Dale

  公开号：US20050222176A1

  公开（公告）日：2005-10-06

  The invention relates to 5-HT receptor modulators, particularly 5-HT 2B antagonists. Novel piperidinylamino-thieno [2,3-d] pyrimidine compounds represented by Formula I, II and III, and uses thereof for treating conditions including pulmonary arterial hypertension, congestive heart failure, and hypertension.

  这项发明涉及5-HT受体调节剂，特别是5-HT 2B 拮抗剂。公式I、II和III所代表的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物，以及它们用于治疗包括肺动脉高压、充血性心力衰竭和高血压等疾病的用途。
• New piperidinylamino-thieno[2,3-D] pyrimidine compounds
  申请人：Dhanoa S. Dale

  公开号：US20050222175A1

  公开（公告）日：2005-10-06

  The invention relates to 5-HT receptor antagonists. Novel piperidinylamino-thieno [2,3-d]pyrimidine compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include central nervous system disorders such as pulmonary arterial hypertension, migraine, hypertension, disorders of the gastrointestinal tract, restenosis, asthma, obstructive airway disease, prostatic hyperplasia and priapism, anxiety, depression, schizophrenia, neural injury and stroke. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also provided.

  该发明涉及5-HT受体拮抗剂。公开了由式I表示的新型哌啶基氨基噻吩[2,3-d]嘧啶化合物，以及其合成和用途，用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括中枢神经系统疾病，如肺动脉高压、偏头痛、高血压、胃肠道疾病、再狭窄、哮喘、阻塞性气道疾病、前列腺增生和勃起功能障碍、焦虑、抑郁症、精神分裂症、神经损伤和中风。还提供了制备方法、新型中间体和药用盐。
• Oxo-pyrido[1,2-a]thienopyrimidine compounds and methods for their
  申请人：Warner-Lambert Company

  公开号：US04230707A1

  公开（公告）日：1980-10-28

  Oxo-pyrido[1,2-a]thienopyrimidine compounds, salts thereof, methods of production, intermediates in their production, pharmaceutical compositions containing said compounds and methods for treating allergies using said compositions are disclosed.

  氧杂噻吡咯并[1,2-a]噻唑嘧啶化合物，其盐，生产方法，生产中间体，含有该化合物的药物组成物和使用该组成物治疗过敏的方法被披露。
• [EN] THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C<br/>[FR] INHIBITEURS DE TYPE THIÉNOPYRIMIDINE DE PROTÉINES KINASES C ATYPIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2013078126A1

  公开（公告）日：2013-05-30

  The present invention provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐，其中R1、R2、R3、R4、R5、R6、A、G、M、Q和X如本文所定义。式（I）的化合物及其盐具有PKC抑制活性，并可用于治疗增生性疾病。